Table 2.
Antibacterial drug susceptibilities of 30 recent uropathogenic E. coli isolates and ATCC strain 25922
| E. coli isolate | Antibacterial drug* | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AM | SAM | PIP | TZP | CZ | CTT | CRO | FEP | MEM | CIP | LVX | SXT | F/M | NN | GM | |
| GLMC 515 | S† | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1117326 | R | R | R | S | S | S | S | S | S | S | S | R | S | S | S |
| GLMC 9 | R | R | R | S | S | S | S | S | S | S | – | S | – | – | S |
| ATCC 25922 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 505 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1123039 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 15 | R | R | I | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1118891 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| CV1119511 | S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 506 | R | I | S | S | S | S | S | S | S | S | – | S | S | – | S |
| GLMC 513 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| GLMC 509 | R | S | R | S | I | S | S | S | S | S | – | S | S | – | S |
| CV1125109 | R | R | R | S | S | S | S | S | S | S | S | R | S | S | S |
| GLMC 503 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1117621 | R | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 514 | S | S | S | S | S | S | S | S | S | S | – | S | S | – | S |
| GLMC 103 | S | S | S | S | S | S | S | S | S | S | – | R | S | – | S |
| CV1121147 | R | S | S | S | S | S | S | S | S | S | S | R | S | S | S |
| CV1117292 | R | I | I | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 101 | R | R | S | S | S | S | S | S | S | S | – | S | S | – | S |
| GLMC 106 | R | I | I | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1119429 | R | I | S | S | S | S | S | S | S | S | S | S | S | S | S |
| GLMC 100 | R | R | S | S | S | S | S | S | S | S | – | S | S | – | S |
| CV1131494 | R | I | S | S | S | S | S | S | S | R | R | S | S | I | R |
| CV1118322 | R | I | S | S | S | S | S | S | S | R | R | S | S | I | R |
| CV1117298 | R | I | R | S | S | S | S | S | S | R | R | R | S | S | S |
| GLMC 508 | R | R | I | S | R | S | S | S | S | R | – | R | S | – | S |
| CV1119857 | R | R | I | S | R | S | S | S | S | R | S | S | S | S | R |
| GLMC 10 | R | I | S | S | S | S | S | S | S | S | – | R | S | – | S |
| GLMC 21 | R | R | I | S | S | S | S | S | S | S | – | S | S | – | S |
*The following antibacterial drugs were used: AM, ampicillin; SAM, ampicillin/sulbactam; PIP, piperacillin; TZP, piperacillin/tazobactam; CZ, cefazolin; CTT, cefotetan; CRO, ceftriaxone; FEP, cefepime; MEM, meropenem; CIP, ciprofloxacin; LVX, levofloxacin; SXT, trimethoprim/sulfa; F/M, nitrofurantoin; NN, tobramycin; GM, gentamicin.
†S, Susceptible; I, intermediate; R, resistant; –, not determined.